PASSKEY Trademark

Trademark Overview

On Thursday, October 5, 2023, a trademark application was filed for PASSKEY with the United States Patent and Trademark Office. The USPTO has given the PASSKEY trademark a serial number of 98211025. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Thursday, September 25, 2025. This trademark is owned by Passkey Therapeutics, Inc.. The PASSKEY trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for the treatment of cancer, immunological diseases, metabolic diseases, and neurodegenerative diseases
passkey

General Information

Serial Number98211025
Word MarkPASSKEY
Filing DateThursday, October 5, 2023
Status731 - SECOND EXTENSION - GRANTED
Status DateThursday, September 25, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, August 6, 2024

Trademark Statements

Goods and ServicesPharmaceuticals for the treatment of cancer, immunological diseases, metabolic diseases, and neurodegenerative diseases

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateSaturday, October 14, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NamePasskey Therapeutics, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139
Party NamePasskey Therapeutics, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCambridge, MA 02139

Trademark Events

Event DateEvent Description
Monday, October 9, 2023NEW APPLICATION ENTERED
Saturday, October 14, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, May 25, 2024NON-FINAL ACTION WRITTEN
Saturday, May 25, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, May 25, 2024NON-FINAL ACTION E-MAILED
Saturday, May 25, 2024ASSIGNED TO EXAMINER
Wednesday, June 12, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, June 12, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, June 12, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, June 29, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 17, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, August 6, 2024PUBLISHED FOR OPPOSITION
Tuesday, August 6, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, October 1, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, February 7, 2025SOU TEAS EXTENSION RECEIVED
Friday, February 7, 2025SOU EXTENSION 1 FILED
Friday, February 7, 2025SOU EXTENSION 1 GRANTED
Friday, February 7, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, March 12, 2025DIVISIONAL REQUEST RECEIVED
Wednesday, March 12, 2025TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, June 10, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Monday, September 22, 2025DIVISIONAL PROCESSING COMPLETE
Monday, September 22, 2025CORRECTED NOA E-MAILED
Tuesday, September 23, 2025SOU EXTENSION 2 FILED
Tuesday, September 23, 2025SOU TEAS EXTENSION RECEIVED
Wednesday, September 24, 2025CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, September 25, 2025SOU EXTENSION 2 GRANTED
Thursday, September 25, 2025NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED

Related Keywords

passkey diseases metabolic neurodegenerative immunological treatment cancer pharmaceuticals